Mucin 1 (MUC1) is a membrane-bound and secreted glycoprotein that has a protective role in surface epithelia. We recently demonstrated that MUC1 mRNA expression was upregulated in tumour-free tongue tissues adjacent to squamous cell carcinoma of the oral tongue (SCCOT) compared with that in the tumour tissues. The present study investigated MUC1 protein in SCCOT tissue and serum from patients with squamous cell carcinoma of the head and neck (SCCHN) at different sub-sites. The results from immunohistochemistry demonstrated that all SCCOT tissues expressed MUC1; however, the protein levels were not correlated with MUC1 mRNA levels in the same tumours. Furthermore, serum MUC1 level was lower in patients with SCCOT, tonsil SCC and gingival SCC compared with that in healthy subjects; however, the difference was only significant for patients with SCCOT (P=0.0421). No correlation was seen between MUC1 level in tumour tissues and MUCI level in serum from the same patients. The absence of correlation between MUC1 protein and mRNA levels in SCCOT tissues emphasized the importance of validating genomic data in clinical samples. Although significant MUC1 downregulation was observed in the serum of patients with SCCOT, there was a large variation within the groups, suggesting that MUC1 may not be used as a biomarker for these types of tumors.

Department of Clinical Sciences Umeå University Hospital Umeå Västerbotten 901 87 Sweden

Department of Medical Biosciences Umeå University Umeå Västerbotten 901 87 Sweden

Institute of Molecular Genetics University of Paris St Louis Hospital Paris Île de France 750 10 France

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Southern Moravia 656 53 Czech Republic

See more in PubMed

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Lubin JH, Purdue M, Kelsey K, Zhang ZF, Winn D, Wei Q, Talamini R, Szeszenia-Dabrowska N, Sturgis EM, Smith E, et al. Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: A pooled analysis of case-control studies. Am J Epidemiol. 2009;170:937–947. doi: 10.1093/aje/kwp222. PubMed DOI PMC

Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P, Møller B, Pukkala E, Schiller TJ, Youngman L, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344:1125–1131. doi: 10.1056/NEJM200104123441503. PubMed DOI

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254. PubMed DOI

Agra IM, Carvalho AL, Pinto CA, Martins EP, Filho JG, Soares FA, Kowalski LP. Biological markers and prognosis in recurrent oral cancer after salvage surgery. Arch Otolaryngol Head Neck Surg. 2008;134:743–749. doi: 10.1001/archotol.134.7.743. PubMed DOI

Carvalho AL, Magrin J, Kowalski LP. Sites of recurrence in oral and oropharyngeal cancers according to the treatment approach. Oral Dis. 2003;9:112–118. doi: 10.1034/j.1601-0825.2003.01750.x. PubMed DOI

Sgaramella N, Gu X, Boldrup L, Coates PJ, Fahraeus R, Califano L, Tartaro G, Colella G, Spaak LN, Strom A, et al. Searching for new targets and treatments in the battle against squamous cell carcinoma of the head and neck, with specific focus on tumours of the tongue. Curr Top Med Chem. 2018;18:214–218. doi: 10.2174/1568026618666180116121624. PubMed DOI

Li G, Da M, Zhang W, Wu H, Ye J, Chen J, Ma L, Gu N, Wu Y, Song X. Alteration of serum lipid profile and its prognostic value in head and neck squamous cell carcinoma. J Oral Pathol Med. 2016;45:167–172. doi: 10.1111/jop.12344. PubMed DOI

Schaaij-Visser TB, Brakenhoff RH, Leemans CR, Heck AJ, Slijper M. Protein biomarker discovery for head and neck cancer. J Proteomics. 2010;73:1790–1803. doi: 10.1016/j.jprot.2010.01.013. PubMed DOI

Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, McClean MD, Kelsey KT. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2007;16:108–114. doi: 10.1158/1055-9965.EPI-06-0636. PubMed DOI

Boldrup L, Gu X, Coates PJ, Norberg-Spaak L, Fahraeus R, Laurell G, Wilms T, Nylander K. Gene expression changes in tumor free tongue tissue adjacent to tongue squamous cell carcinoma. Oncotarget. 2017;8:19389–19402. doi: 10.18632/oncotarget.14288. PubMed DOI PMC

van Putten JPM, Strijbis K. Transmembrane mucins: Signaling receptors at the intersection of inflammation and cancer. J Innate Immun. 2017;9:281–299. doi: 10.1159/000453594. PubMed DOI PMC

Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: An immunohistochemical study. Am J Clin Pathol. 2004;122:61–69. doi: 10.1309/9R6673QEC06D86Y4. PubMed DOI

Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011;4:ra9. doi: 10.1126/scisignal.2001426. PubMed DOI PMC

Carson DD. The cytoplasmic tail of MUC1: A very busy place. Sci Signal. 2008;1:pe35. doi: 10.1126/scisignal.127pe35. PubMed DOI

Thathiah A, Carson DD. MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17. Biochem J. 2004;382:363–373. doi: 10.1042/BJ20040513. PubMed DOI PMC

Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and prognostic significance of cancer antigen 15-3 and carcinoembryonic antigen in breast cancer: A meta-analysis including 12,993 patients. Dis Markers. 2018;2018:9863092. doi: 10.1155/2018/9863092. PubMed DOI PMC

Angadi PV, Savitha JK, Rao SS, Sivaranjini Y. Oral field cancerization: Current evidence and future perspectives. Oral Maxillofac Surg. 2012;16:171–180. doi: 10.1007/s10006-012-0317-x. PubMed DOI

Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field effect: Reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol. 2015;28:14–29. doi: 10.1038/modpathol.2014.81. PubMed DOI PMC

Sobin LH, Gospodarowicz MK, Wittekind C. 7th. Wiley-Blackwell; Chichester, West Sussex: 2009. TNM classification of malignant tumours.

Detre S, Saclani Jotti G, Dowsett M. A ‘quickscore’ method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876–878. doi: 10.1136/jcp.48.9.876. PubMed DOI PMC

Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7. doi: 10.1016/j.cell.2005.06.036. PubMed DOI

Kumar MH, Sanjai K, Kumarswamy J, Keshavaiah R, Papaiah L, Divya S. Expression of MUC1 mucin in potentially malignant disorders, oral squamous cell carcinoma and normal oral mucosa: An immunohistochemical study. J Oral Maxillofac Pathol. 2016;20:214–218. doi: 10.4103/0973-029X.185916. PubMed DOI PMC

Nitta T, Sugihara K, Tsuyama S, Murata F. Immunohistochemical study of MUC1 mucin in premalignant oral lesions and oral squamous cell carcinoma: Association with disease progression, mode of invasion, and lymph node metastasis. Cancer. 2000;88:245–254. doi: 10.1002/(SICI)1097-0142(20000115)88:2<245::AID-CNCR1>3.0.CO;2-T. PubMed DOI

de Sousa Abreu R, Penalva LO, Marcotte EM, Vogel C. Global signatures of protein and mRNA expression levels. Mol Biosyst. 2009;5:1512–1526. PubMed PMC

Maier T, Guell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett. 2009;583:3966–3973. doi: 10.1016/j.febslet.2009.10.036. PubMed DOI

Safi F, Kohler I, Rottinger E, Beger H. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen. Cancer. 1991;68:574–582. doi: 10.1002/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B. PubMed DOI

Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–355. PubMed

Duffy MJ, Duggan C, Keane R, Hill ASK, McDermott E, Crown J, O'Higgins N. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559–563. doi: 10.1373/clinchem.2003.025288. PubMed DOI

Duffy MJ, Evoy D, McDermott EW. CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411:1869–1874. doi: 10.1016/j.cca.2010.08.039. PubMed DOI

Boldrup L, Coates PJ, Laurell G, Nylander K. Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncol. 2011;47:861–865. doi: 10.1016/j.oraloncology.2011.07.002. PubMed DOI

Boldrup L, Coates PJ, Wahlgren M, Laurell G, Nylander K. Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins. J Carcinog. 2012;11:18. doi: 10.4103/1477-3163.104007. PubMed DOI PMC

Ledgerwood LG, Kumar D, Eterovic AK, Wick J, Chen K, Zhao H, Tazi L, Manna P, Kerley S, Joshi R, et al. The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget. 2016;7:27185–27198. doi: 10.18632/oncotarget.8448. PubMed DOI PMC

De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, et al. Activity of eribulin in a primary culture of well-differentiated/dedifferentiated adipocytic sarcoma. Molecules. 2016;21:1662. doi: 10.3390/molecules21121662. PubMed DOI PMC

Oppel F, Shao S, Schurmann M, Goon P, Albers AE, Sudhoff H. An effective primary head and neck squamous cell carcinoma in vitro model. Cells. 2019;8:555. doi: 10.3390/cells8060555. PubMed DOI PMC

Yuan Z, Wong S, Borrelli A, Chung MA. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun. 2007;362:740–746. doi: 10.1016/j.bbrc.2007.08.074. PubMed DOI

Tanimoto T, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. MUC1 expression in intramucosal colorectal neoplasms. Possible involvement in histogenesis and progression. Oncology. 1999;56:223–231. doi: 10.1159/000011969. PubMed DOI